Niveles séricos de magnesio en perros sanos sometidos a la administración de cisplatino con terapia de líquidos Translated title: Serum magnesium levels in healthy dogs submitted to the administration of cisplatin with fluid therapy

Abstract

El cisplatino es un agente antineoplásico útil para el tratamiento de carcinomas y osteosarcomas en perros; sin embargo, puede causar daño renal que resulta con pérdida de electrólitos. Se evaluó la concentración de magnesio en suero sanguíneo de ocho caninos sometidos a terapia con cisplatino, distribuidos en dos grupos. A los perros del Grupo 1 se les administró cisplatino (70 mg/m², iv), para prevenir la nefrotoxicidad recibieron solución salina al 0.9% (25 ml/kg/h, iv durante tres horas). Los animales del Grupo 2 no recibieron cisplatino. No hubo diferencia significativa (P < 0.05) entre grupos, los resultados obtenidos indican que el protocolo utilizado para el Grupo 1 no ocasionó cambios en la concentración sérica de magnesio. Por tanto, se concluye que la administración de cisplatino no ocasiona estos cambios si se aplica juntamente con terapia de líquidos.

Translated abstract

Cisplatin is an antineoplastic drug that is used to treat carcinomas and osteosarcomas in dogs. However, it can cause kidney damage which in turn leads to the loss of electrolytes. Concentration of magnesium was evaluated in the blood serum of eight dogs that had undergone therapy with cisplatin. The dogs were divided into two groups. Group 1 was supply with cisplatin (70 mg/m², iv) and to prevent nephrotoxcity, saline solution at 0.9% was administered (25 ml/kg/hour, iv in three hours). The animals in Group 2 were not supplied with cisplatin. There was no significant difference (P < 0.05) between the two groups and the results obtained indicated that the protocol used for Group 1 did not cause changes in the serum concentrations of magnesium. Therefore, it can be concluded that the administration of cisplatin does not cause variations if it is combined with the fuid therapy.